Logo

AstraZeneca Reports Pooled Cardiovascular Safety and Efficacy Analyses of Roxadustat in P-III Program for CKD Patients with Anaemia

Share this

AstraZeneca Reports Pooled Cardiovascular Safety and Efficacy Analyses of Roxadustat in P-III Program for CKD Patients with Anaemia

Shots:

  • The P-III program involves assessing of Roxadustat vs PBO and epoetin alfa in 9-000+ NDD and DD & ID patients in multiple studies conducted by AstraZeneca- FibroGen and Astellas together globally respectively
  • Results: The risk of MACE- MACE+ and all-cause mortality & Hb level (1.85 g/dL vs 0.13 g/dL) in NDD patients was comparable to PBO- showed 30% lower risk of MACE and 34% lower risk of MACE+ with a trend towards lower all-cause mortality in ID patients- no increased risk of MACE and all-cause mortality and a lower risk of MACE+- Hb level (1.22 g/dL vs 0.99 g/dL) in DD patients
  • Roxadustat is a first-in-class- hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) being evaluated for the treatment of anaemia in CKD. The results from pooled analysis served as a basis for its anticipated regulatory submission in the US in Q4’19

Click here to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions